These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8253917)

  • 1. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.
    Delvigne A; Demoulin A; Smitz J; Donnez J; Koninckx P; Dhont M; Englert Y; Delbeke L; Darcis L; Gordts S
    Hum Reprod; 1993 Sep; 8(9):1353-60. PubMed ID: 8253917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction.
    Delvigne A; Dubois M; Battheu B; Bassil S; Meuleman C; De Sutter P; Rodesch C; Janssens P; Remacle P; Gordts S
    Hum Reprod; 1993 Sep; 8(9):1361-6. PubMed ID: 8253918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro fertilization and the ovarian hyperstimulation syndrome.
    MacDougall MJ; Tan SL; Jacobs HS
    Hum Reprod; 1992 May; 7(5):597-600. PubMed ID: 1639974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme.
    Imoedemhe DA; Chan RC; Sigue AB; Pacpaco EL; Olazo AB
    Hum Reprod; 1991 Sep; 6(8):1088-91. PubMed ID: 1806566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there predictive criteria of complicated ovarian hyperstimulation in IVF?
    Delvigne A; Vandromme J; Barlow P; Lejeune B; Leroy F
    Hum Reprod; 1991 Aug; 6(7):959-62. PubMed ID: 1761666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.
    Lyons CA; Wheeler CA; Frishman GN; Hackett RJ; Seifer DB; Haning RV
    Hum Reprod; 1994 May; 9(5):792-9. PubMed ID: 7929724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.
    Rizk B; Smitz J
    Hum Reprod; 1992 Mar; 7(3):320-7. PubMed ID: 1587936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme.
    Graf MA; Fischer R; Naether OG; Baukloh V; Tafel J; Nückel M
    Hum Reprod; 1997 Dec; 12(12):2599-602. PubMed ID: 9455820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.
    Enskog A; Henriksson M; Unander M; Nilsson L; Brännström M
    Fertil Steril; 1999 May; 71(5):808-14. PubMed ID: 10231037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Some aspects of ovarian hyperstimulation syndrome].
    Kovachev E; Kozovski I; Markova V; Andronov M; Cherneva S; Aleksandrov K
    Akush Ginekol (Sofiia); 2003; 42(6):37-41. PubMed ID: 15067814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome.
    Shalev E; Geslevich Y; Ben-Ami M
    Hum Reprod; 1994 Mar; 9(3):417-9. PubMed ID: 8006128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update on ovarian hyperstimulation syndrome].
    Delbaere A; Rodesch C; Englert Y
    Rev Med Brux; 1995 Nov; 16(5):354-60. PubMed ID: 7501911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.
    de Jong D; Macklon NS; Mannaerts BM; Coelingh Bennink HJ; Fauser BC
    Hum Reprod; 1998 Mar; 13(3):573-5. PubMed ID: 9572414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.